Mumbai, Feb. 10 -- French pharmaceutical group Servier has announced the establishment of a global platform in India dedicated to the development, manufacturing and export of Single Pill Combinations for cardiometabolic and venous diseases, reinforcing its long-term commitment to the Indian market.
The platform named GATINN, was unveiled in Mumbai on Tuesday and represents a key step in Servier's 2030 ambition to accelerate patient-centric innovation.
Servier said it plans to invest around 15 million euro in 2026 to build the GATINN platform in collaboration with Indian partners. The initiative aims to simplify treatment regimens through high-quality Single Pill Combinations, thereby improving patient adherence and long-term outcomes in c...